SCHEMBL6490953

SCHEMBL6490953

CC(=O)c1ccc(-c2ccccc2CCNC(=O)CC2NC(=O)NC2=O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.47
ALDH1A1 P00352 12/20 0.47
TAAR1 Q96RJ0 3/20 0.47
GAA P10253 5/20 0.46
KDM1A O60341 1/20 0.46
HSD17B10 Q99714 8/20 0.44
MAPT P10636 6/20 0.44
HPGD P15428 4/20 0.44
POLB P06746 3/20 0.44
MAPK1 P28482 2/20 0.44
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
HTT P42858 1/20 0.42
CASP1 P29466 1/20 0.42
BLM P54132 1/20 0.42
MCL1 Q07820 1/20 0.42
PLEC Q15149 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TP53 P04637 1/20 0.41
ALOX15 P16050 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6527932 0.89 KDM4E (0.49) KDM4EALDH1A1TAAR1GAAKDM1A
SCHEMBL2865070 0.84 ALDH1A1 (0.54) KDM4EALDH1A1TAAR1GAAKDM1A
SCHEMBL6493317 0.80 KDM4E (0.48) KDM4EALDH1A1TAAR1GAAHSD17B10
SCHEMBL2872967 0.79 KDM1A (0.46) KDM4EALDH1A1TAAR1GAAKDM1A
SCHEMBL2868863 0.77 ALDH1A1 (0.58) KDM4EALDH1A1TAAR1GAAHSD17B10
SCHEMBL2870661 0.76 ALDH1A1 (0.67) KDM4EALDH1A1TAAR1GAAKDM1A
SCHEMBL2869386 0.76 ALDH1A1 (0.67) KDM4EALDH1A1TAAR1GAAKDM1A
SCHEMBL2872252 0.74 ALDH1A1 (0.47) KDM4EALDH1A1TAAR1GAAHSD17B10
SCHEMBL2872441 0.73 ALDH1A1 (0.56) KDM4EALDH1A1TAAR1GAAHSD17B10
SCHEMBL2876072 0.73 HPGD (0.53) KDM4EALDH1A1TAAR1GAAKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050245586-A1 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12 ASTRAZENECA AB (SE) 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245586-A1 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12 MMP12, PDE12, MMP13 KDM4E 553/4885ALDH1A1 441/4885TAAR1 3540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.